The controlled multi-centre, randomised, prospective trial is investigating the therapy in kidney transplant recipients.

While development has been scrapped in CMV, a Phase II trial investigating the candidate in bone marrow transplant patients ...

The study, titled “ Strategic Help with Immunoglobulin to Enhance protection against Late Disease (CMV) ” or SHIELD, is a prospective, randomized, controlled multicenter investigator-initiated study ...

Declining immune responsiveness with age may be driven by changes in immune cells — not by inflammation, as previously ...

(NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the ...

Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven ...

A shot analysts projected as a multibillion-dollar seller produced results “well below” the company’s expectations, ...

Topline results were announced from a phase 3 study evaluating Moderna’s cytomegalovirus vaccine candidate, mRNA-1647.

Moderna has decided to halt the development of its mRNA-1647 vaccine for congenital cytomegalovirus (CMV) infections – once ...

A comprehensive eight-year study examining audiological outcomes of newborns screened for congenital cytomegalovirus (cCMV) ...

Laura Gibson is an associate professor of medicine and of pediatrics at UMass Chan Medical School. CMV belongs to the same virus family as cold sores and chickenpox and, like those viruses, lives in ...

March 19, 2009 — Cytomegalovirus (CMV) glycoprotein B vaccine may help prevent maternal and congenital CMV infection, according to the results of a phase 2, randomized, double-blind, controlled trial ...